SavedAdd your journal

Journals / Kadın Sağlığı Hemşireliği Dergisi / 2026 / Cilt: 7 Sayı: 1

CURRENT PRENATAL SCREENING TEST: Cell Free Fetal DNA Analysis

Güncel Prenatal Tarama Testi: Hücreden Serbest Fetal DNA Analizi

Elif Doğan(İSTANBUL ÜNİVERSİTESİ - CERRAHPAŞA)0000-0003-3374-1764
Hüsniye Dinç(İSTANBUL ÜNİVERSİTESİ - CERRAHPAŞA)0000-0002-8461-643X
Pages
71–84
Publication Date
2021-03-31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Bu derlemenin amacı; cfDNA ile ilgili güncel literatür bilgisini paylaşmaktır.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Prenatal tarama testlerinin kullanımı 1970’li yıllarda maternal yaşın değerlendirilmesiyle başlamış; bu serüven maternal yaş, fetal ense kalınlığı ve maternal serum markerlarının kombinasyonlu kullanımıyla devam etmiştir.
📊
Key Findings & Data:Aradan geçen 50 yılın ardından prenatal tarama testlerinin geldiği son nokta ise maternal kanda hücreden serbest DNA (cfDNA)’nın analizi olmuştur.
💡
Conclusion & Impact:Bu derlemenin amacı; cfDNA ile ilgili güncel literatür bilgisini paylaşmaktır.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Hücreden serbest DNA · cfDNA · non invaziv prenatal test

Abstract

Prenatal tarama testlerinin kullanımı 1970’li yıllarda maternal yaşın değerlendirilmesiyle başlamış; bu serüven maternal yaş, fetal ense kalınlığı ve maternal serum markerlarının kombinasyonlu kullanımıyla devam etmiştir. Aradan geçen 50 yılın ardından prenatal tarama testlerinin geldiği son nokta ise maternal kanda hücreden serbest DNA (cfDNA)’nın analizi olmuştur. Günümüzde hala geleneksel tarama testleri rutin olarak uygulanmasına rağmen cfDNA analizi özellikle yaygın anöploidilerin saptanmasında yüksek başarı göstermekte, hatta trizomi 21 için en güvenilir test olarak değerlendirilmektedir. Yine de bu başarısını genel popülasyonda ve tüm anomalilerin taranmasında koruyamaması cfDNA’yı rutin tarama olarak kullanım dışı bırakmaktadır. cfDNA sonucunu etkileyen faktörlerin varlığı ve düşük dahi olsa yalancı pozitiflik değerinin bulunması cfDNA’nın pozitif sonuç durumlarında invaziv testlerle onaylanmasını zorunlu kılmaktadır. Bu nedenle hala hangi popülasyonda uygulanabileceği tartışması güncelliğini korumaktadır. Bu derlemenin amacı; cfDNA ile ilgili güncel literatür bilgisini paylaşmaktır.

Özet

Prenatal tarama testlerinin kullanımı 1970’li yıllarda maternal yaşın değerlendirilmesiyle başlamış; bu serüven maternal yaş, fetal ense kalınlığı ve maternal serum markerlarının kombinasyonlu kullanımıyla devam etmiştir. Aradan geçen 50 yılın ardından prenatal tarama testlerinin geldiği son nokta ise maternal kanda hücreden serbest DNA (cfDNA)’nın analizi olmuştur. Günümüzde hala geleneksel tarama testleri rutin olarak uygulanmasına rağmen cfDNA analizi özellikle yaygın anöploidilerin saptanmasında yüksek başarı göstermekte, hatta trizomi 21 için en güvenilir test olarak değerlendirilmektedir. Yine de bu başarısını genel popülasyonda ve tüm anomalilerin taranmasında koruyamaması cfDNA’yı rutin tarama olarak kullanım dışı bırakmaktadır. cfDNA sonucunu etkileyen faktörlerin varlığı ve düşük dahi olsa yalancı pozitiflik değerinin bulunması cfDNA’nın pozitif sonuç durumlarında invaziv testlerle onaylanmasını zorunlu kılmaktadır. Bu nedenle hala hangi popülasyonda uygulanabileceği tartışması güncelliğini korumaktadır. Bu derlemenin amacı; cfDNA ile ilgili güncel literatür bilgisini paylaşmaktır.

🔖

Cite This Article

Doğan, E., Dinç, H. (2021). CURRENT PRENATAL SCREENING TEST: Cell Free Fetal DNA Analysis. Kadın Sağlığı Hemşireliği Dergisi, Cilt: 7 Sayı: 1, 71–84. https://ajindex.com/articles/1516193

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (58)

  1. American College of Obstetricians and Gynecologists (ACOG) Committee on Genetics (2012). Committee Opinion No. 545: Noninvasive prenatal testing for fetal aneuploidy. Obstetrics and Gynecology, 120(6), 1532–1534. https://doi.org/10.1097/01.AOG.0000423819.85283.f4
  2. American College of Obstetricians and Gynecologists (ACOG) Committee on Genetics & Society for Maternal Fetal Medicine (SMFM). (2016). Practice Bulletin No. 163: Screening for Fetal Aneuploidy. Obstetrics and gynecology, 127(5), e123–e137. https://doi.org/10.1097/AOG.0000000000001406
  3. Benn, P., Borrell, A., Chiu, R. W., Cuckle, H., Dugoff, L., Faas, B. … Yaron, Y. (2015). Position statement from the Chromosome Abnormality Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenatal Diagnosis, 35(8), 725–734. https://doi.org/10.1002/pd.4608
  4. Benn, P., Valenti, E., Shah, S., Martin, K., & Demko, Z. (2018). Factors Associated With Informative Redraw After an Initial No Result in Noninvasive Prenatal Testing. Obstetrics and Gynecology, 132(2), 428–435. https://doi.org/10.1097/AOG.0000000000002728
  5. Bianchi, D. W., Chudova, D., Sehnert, A. J., Bhatt, S., Murray, K., Prosen, T. L. … Halks-Miller, M. (2015). Noninvasive Prenatal Testing and Incidental Detection of Occult Maternal Malignancies. JAMA, 314(2), 162–169. https://doi.org/10.1001/jama.2015.7120
  6. Bianchi, D. W., Parker, R. L., Wentworth, J., Madankumar, R., Saffer, C., Das, A. F. … CARE Study Group (2014). DNA sequencing versus standard prenatal aneuploidy screening. The New England Journal of Medicine, 370(9), 799–808. https://doi.org/10.1056/NEJMoa1311037
  7. Burns, W., Koelper, N., Barberio, A., Deagostino-Kelly, M., Mennuti, M., Sammel, M. D., & Dugoff, L. (2017). The association between anticoagulation therapy, maternal characteristics, and a failed cfDNA test due to a low fetal fraction. Prenatal Diagnosis, 37(11), 1125–1129. https://doi.org/10.1002/pd.5152
  8. Cheng, S. B., Davis, S., & Sharma, S. (2018). Maternal-fetal cross talk through cell-free fetal DNA, telomere shortening, microchimerism, and inflammation. American Journal of Reproductive Immunology (New York, N.Y.: 1989), 79(5), e12851. https://doi.org/10.1111/aji.12851
  9. Contro, E., Bernabini, D., & Farina, A. (2017). Cell-Free Fetal DNA for the Prediction of Pre-Eclampsia at the First and Second Trimesters: A Systematic Review and Meta-Analysis. Molecular Diagnosis & Therapy, 21(2), 125–135. https://doi.org/10.1007/s40291-016-0245-9
  10. Cotarelo-Pérez, C., Oancea-Ionescu, R., Asenjo-de-la-Fuente, E., Ortega-de-Heredia, D., Soler-Ruiz, P., Coronado-Martín, P., & Fenollar-Cortés, M. (2019). A contingent model for cell-free DNA testing to detect fetal aneuploidy after first trimester combined screening. European Journal of Obstetrics & Gynecology and Reproductive Biology: X, 1, 100002. https://doi.org/10.1016/j.eurox.2019.100002
  11. Curnow, K. J., Wilkins-Haug, L., Ryan, A., Kırkızlar, E., Stosic, M., Hall, M. P. … Gross, S. J. (2015). Detection of triploid, molar, and vanishing twin pregnancies by a single-nucleotide polymorphism-based noninvasive prenatal test. American Journal of Obstetrics and Gynecology, 212(1), 79.e1–79.e799. https://doi.org/10.1016/j.ajog.2014.10.012
  12. Gerson, K. D., Truong, S., Haviland, M. J., O'Brien, B. M., Hacker, M. R., & Spiel, M. H. (2019). Low fetal fraction of cell-free DNA predicts placental dysfunction and hypertensive disease in pregnancy. Pregnancy Hypertension, 16, 148–153. https://doi.org/10.1016/j.preghy.2019.04.002
  13. Gil, M. M., Accurti, V., Santacruz, B., Plana, M. N., & Nicolaides, K. H. (2017). Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis. Ultrasound in Obstetrics & Gynecology: The Official Journal of The International Society of Ultrasound in Obstetrics and Gynecology, 50(3), 302–314. https://doi.org/10.1002/uog.17484
  14. Gil, M. M., Quezada, M. S., Revello, R., Akolekar, R., & Nicolaides, K. H. (2015). Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound in Obstetrics & Gynecology: The Official Journal of The International Society of Ultrasound in Obstetrics and Gynecology, 45(3), 249–266. https://doi.org/10.1002/uog.14791
  15. Goldwaser, T., & Klugman, S. (2018). Cell-free DNA for the detection of fetal aneuploidy. Fertility and Sterility, 109(2), 195–200. https://doi.org/10.1016/j.fertnstert.2017.12.019
  16. Gregg, A. R., Skotko, B. G., Benkendorf, J. L., Monaghan, K. G., Bajaj, K., Best, R. G. … Watson, M. S. (2016). Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics. Genetics in Medicine: Official Journal of The American College of Medical Genetics, 18(10), 1056–1065. https://doi.org/10.1038/gim.2016.97
  17. Hartwig, T. S., Ambye, L., Werge, L., Weiergang, M. K., Nørgaard, P., Sørensen, S., & Jørgensen, F. S. (2018). Non-Invasive Prenatal Testing (NIPT) in pregnancies with trisomy 21, 18 and 13 performed in a public setting - factors of importance for correct interpretation of results. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 226, 35–39. https://doi.org/10.1016/j.ejogrb.2018.04.042
  18. Herrera, C. A., Stoerker, J., Carlquist, J., Stoddard, G. J., Jackson, M., Esplin, S., & Rose, N. C. (2017). Cell-free DNA, inflammation, and the initiation of spontaneous term labor. American Journal of Obstetrics and Gynecology, 217(5), 583.e1–583.e8. https://doi.org/10.1016/j.ajog.2017.05.027
  19. Hui, L. (2016). Noninvasive prenatal testing for aneuploidy using cell-free DNA - New implications for maternal health. Obstetric Medicine, 9(4), 148–152. https://doi.org/10.1177/1753495X16652007
  20. Jain, M., Balatsky, A. V., Revina, D. B., & Samokhodskaya, L. M. (2019). Direct comparison of QIAamp DSP Virus Kit and QIAamp Circulating Nucleic Acid Kit regarding cell-free fetal DNA isolation from maternal peripheral blood. Molecular and Cellular Probes, 43, 13–19. https://doi.org/10.1016/j.mcp.2018.12.006
  21. Kageleiry, A., Samuelson, D., Duh, M. S., Lefebvre, P., Campbell, J., & Skotko, B. G. (2017). Out-of-pocket medical costs and third-party healthcare costs for children with Down syndrome. American Journal of Medical Genetics. Part A, 173(3), 627–637. https://doi.org/10.1002/ajmg.a.38050
  22. Kazachkova, N., Gontar, J., Verlinsky, O., & Ilyin, I. (2019). Successful early fetal sex determination using cell-free fetal DNA isolated from maternal capillary blood: A pilot study. European Journal of Obstetrics & Gynecology and Reproductive Biology: X, 3, 100038. https://doi.org/10.1016/j.eurox.2019.100038
  23. Li, W. H., Wang, P. H., Chuang, C. M., Chang, Y. W., Yang, M. J., Chen, C. Y. … Yen, M. S. (2015). Noninvasive prenatal testing for fetal trisomy in a mixed risk factors pregnancy population. Taiwanese Journal of Obstetrics & Gynecology, 54(2), 122–125. https://doi.org/10.1016/j.tjog.2015.02.001
  24. Lo, Y. M., Corbetta, N., Chamberlain, P. F., Rai, V., Sargent, I. L., Redman, C. W., & Wainscoat, J. S. (1997). Presence of fetal DNA in maternal plasma and serum. Lancet (London, England), 350(9076), 485–487. https://doi.org/10.1016/S0140-6736(97)02174-0
  25. Lund, I., Becher, N., Christensen, R., Petersen, O. B., Steffensen, E. H., Vestergaard, E. M., & Vogel, I. (2020). Prevalence of mosaicism in uncultured chorionic villus samples after chromosomal microarray and clinical outcome in pregnancies affected by confined placental mosaicism. Prenatal Diagnosis, 40(2), 244–259. https://doi.org/10.1002/pd.5584
  26. Manotaya, S., Xu, H., Uerpairojkit, B., Chen, F., Charoenvidhya, D., Liu, H. … Jiang, H. (2016). Clinical experience from Thailand: noninvasive prenatal testing as screening tests for trisomies 21, 18 and 13 in 4736 pregnancies. Prenatal Diagnosis, 36(3), 224–231. https://doi.org/10.1002/pd.4775
  27. McKanna, T., Ryan, A., Krinshpun, S., Kareht, S., Marchand, K., Grabarits, C. … Benn, P. (2019). Fetal fraction-based risk algorithm for non-invasive prenatal testing: screening for trisomies 13 and 18 and triploidy in women with low cell-free fetal DNA. Ultrasound in Obstetrics & Gynecology: The Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology, 53(1), 73–79. https://doi.org/10.1002/uog.19176
  28. Nicolaides, K. H. (2011). Screening for fetal aneuploidies at 11 to 13 weeks. Prenatal Diagnosis, 31(1), 7–15. https://doi.org/10.1002/pd.2637
  29. Norton, M. E., Jacobsson, B., Swamy, G. K., Laurent, L. C., Ranzini, A. C., Brar, H. … Wapner, R. J. (2015). Cell-free DNA analysis for noninvasive examination of trisomy. The New England Journal of Medicine, 372(17), 1589–1597. https://doi.org/10.1056/NEJMoa1407349
  30. Osborne, C. M., Hardisty, E., Devers, P., Kaiser-Rogers, K., Hayden, M. A., Goodnight, W., & Vora, N. L. (2013). Discordant noninvasive prenatal testing results in a patient subsequently diagnosed with metastatic disease. Prenatal Diagnosis, 33(6), 609–611. https://doi.org/10.1002/pd.4100
  31. Palka, C., Guanciali-Franchi, P., Morizio, E., Alfonsi, M., Papponetti, M., Sabbatinelli, G. … Benn, P. (2019). Non-invasive prenatal screening: A 20-year experience in Italy. European Journal of Obstetrics & Gynecology and Reproductive Biology: X, 3, 100050. https://doi.org/10.1016/j.eurox.2019.100050
  32. Palomaki, G. E., Kloza, E. M., Lambert-Messerlian, G. M., van den Boom, D., Ehrich, M., Deciu, C. … Haddow, J. E. (2015). Circulating cell free DNA testing: are some test failures informative?. Prenatal Diagnosis, 35(3), 289–293. https://doi.org/10.1002/pd.4541
  33. Pös, O., Budiš, J., & Szemes, T. (2019). Recent trends in prenatal genetic screening and testing. F1000Research, 8, F1000 Faculty Rev-764. https://doi.org/10.12688/f1000research.16837.1
  34. Qiao, L., Yu, B., Liang, Y., Zhang, C., Wu, X., Xue, Y. … Wang, T. (2019). Sequencing shorter cfDNA fragments improves the fetal DNA fraction in noninvasive prenatal testing. American Journal of Obstetrics and Gynecology, 221(4), 345.e1–345.e11. https://doi.org/10.1016/j.ajog.2019.05.023
  35. Ren, Y., Zhao, J., Li, R., Xie, Y., Jiang, S., Zhou, H. … Lu, Y. (2018). Noninvasive prenatal test for FGFR3-related skeletal dysplasia based on next-generation sequencing and plasma cell-free DNA: Test performance analysis and feasibility exploration. Prenatal Diagnosis, 38(11), 821–828. https://doi.org/10.1002/pd.5334
  36. Renga, B. (2018). Non invasive prenatal diagnosis of fetal aneuploidy using cell free fetal DNA. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 225, 5–8. https://doi.org/10.1016/j.ejogrb.2018.03.033
  37. Revello, R., Sarno, L., Ispas, A., Akolekar, R., & Nicolaides, K. H. (2016). Screening for trisomies by cell-free DNA testing of maternal blood: consequences of a failed result. Ultrasound in Obstetrics & Gynecology: The Official Journal of The International Society of Ultrasound in Obstetrics and Gynecology, 47(6), 698–704. https://doi.org/10.1002/uog.15851
  38. Rolnik, D. L., da Silva Costa, F., Lee, T. J., Schmid, M., & McLennan, A. C. (2018). Association between fetal fraction on cell-free DNA testing and first-trimester markers for pre-eclampsia. Ultrasound in Obstetrics & Gynecology: The Official Journal of The International Society of Ultrasound in Obstetrics and Gynecology, 52(6), 722–727. https://doi.org/10.1002/uog.18993
  39. Royal College of Obstetricians and Gynaecologists (RCOG). (2014). Scientific Impact Paper No. 15: Non-invasive Prenatal Testing for Chromosomal Abnormality Using Maternal Plasma DNA. Obstet Gynecol, 16: 148-148. https://doi.org/10.1111/tog.12099
  40. Salomon, L. J., Alfirevic, Z., Audibert, F., Kagan, K. O., Paladini, D., Yeo, G. … ISUOG Clinical Standards Committee (2014). ISUOG consensus statement on the impact of non-invasive prenatal testing (NIPT) on prenatal ultrasound practice. Ultrasound in Obstetrics & Gynecology: the Official Journal of The International Society of Ultrasound in Obstetrics and Gynecology, 44(1), 122–123. https://doi.org/10.1002/uog.13393
  41. Sieroszewski, P., Wielgos, M., Radowicki, S., Sasiadek, M., Borowiec, M., Borowski, D. … Moczulska, H. (2017). Cell-free fetal DNA testing in prenatal diagnosis: Recommendations of the Polish Gynecological Society and the Polish Human Genetics Society. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 214, 190–191. https://doi.org/10.1016/j.ejogrb.2017.05.009
  42. Society for Maternal-Fetal Medicine (SMFM) Publications Committee. (2015). #36: Prenatal aneuploidy screening using cell-free DNA. American Journal of Obstetrics and Gynecology, 212(6), 711–716. https://doi.org/10.1016/j.ajog.2015.03.043
  43. Suzumori, N., Sekizawa, A., Ebara, T., Samura, O., Sasaki, A., Akaishi, R. … Sago, H. (2018). Fetal cell-free DNA fraction in maternal plasma for the prediction of hypertensive disorders of pregnancy. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 224, 165–169. https://doi.org/10.1016/j.ejogrb.2018.03.048
  44. Suzumori, N., Sekizawa, A., Takeda, E., Samura, O., Sasaki, A., Akaishi, R. … Sago, H. (2021). Retrospective details of false-positive and false-negative results in non-invasive prenatal testing for fetal trisomies 21, 18 and 13. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 256, 75–81. https://doi.org/10.1016/j.ejogrb.2020.10.050
  45. Thurik, F. F., Lamain-de Ruiter, M., Javadi, A., Kwee, A., Woortmeijer, H., Page-Christiaens, G. C. … Koster, M. P. (2016). Absolute first trimester cell-free DNA levels and their associations with adverse pregnancy outcomes. Prenatal Diagnosis, 36(12), 1104–1111. https://doi.org/10.1002/pd.4940
  46. Tian, Y., Zhang, L., Tian, W., Gao, J., Jia, L., & Cui, S. (2018). Analysis of the accuracy of Z-scores of non-invasive prenatal testing for fetal Trisomies 13, 18, and 21 that employs the ion proton semiconductor sequencing platform. Molecular Cytogenetics, 11, 49. https://doi.org/10.1186/s13039-018-0397-x
  47. Uquillas, K., Chan, Y., King, J. R., Randolph, L. M., & Incerpi, M. (2017). Chorionic villus sampling fails to confirm mosaic trisomy 21 fetus after positive cell-free DNA. Prenatal Diagnosis, 37(3), 296–298. https://doi.org/10.1002/pd.4992
  48. Vogel, I., Vestergaard, E. M., Lildballe, D. L., Christensen, R., Hoseth, G. E., Petersen, A. C. … Sørensen, A. N. (2020). Placental mosaicism in the era of chromosomal microarrays. European Journal of Medical Genetics, 63(4), 103778. https://doi.org/10.1016/j.ejmg.2019.103778
  49. Wang, E., Batey, A., Struble, C., Musci, T., Song, K., & Oliphant, A. (2013). Gestational age and maternal weight effects on fetal cell-free DNA in maternal plasma. Prenatal Diagnosis, 33(7), 662–666. https://doi.org/10.1002/pd.4119
  50. Wilson, K. L., Czerwinski, J. L., Hoskovec, J. M., Noblin, S. J., Sullivan, C. M., Harbison, A. … Singletary, C. N. (2013). NSGC practice guideline: prenatal screening and diagnostic testing options for chromosome aneuploidy. Journal of Genetic Counseling, 22(1), 4–15. https://doi.org/10.1007/s10897-012-9545-3
  51. Yang, X., Zhou, Q., Zhou, W., Zhong, M., Guo, X., Wang, X., … Xu, X. (2019). A Cell-free DNA Barcode-Enabled Single-Molecule Test for Noninvasive Prenatal Diagnosis of Monogenic Disorders: Application to β-Thalassemia. Advanced Science (Weinheim, Baden-Wurttemberg, Germany), 6(11), 1802332. https://doi.org/10.1002/advs.201802332
  52. Yuan, X., Zhou, L., Zhang, B., Wang, H., Yu, B., & Xu, J. (2020). Association between low fetal fraction of cell free DNA at the early second-trimester and adverse pregnancy outcomes. Pregnancy Hypertension, 22, 101–108. https://doi.org/10.1016/j.preghy.2020.07.015
  53. Zhao, Q., HuoJiaBieKe, J., & Du, S. (2019). The influence of fetal gender and maternal characteristics on fetal cell-free DNA in maternal plasma. Journal of Gynecology Obstetrics and Human Reproduction, 48(8), 653–656. https://doi.org/10.1016/j.jogoh.2019.07.001
  54. Cheng, S. B., Davis, S., & Sharma, S. (2018). Maternal-fetal cross talk through cell-free fetal DNA, telomere shortening, microchimerism, and inflammation. American Journal of Reproductive Immunology (New York, N.Y.: 1989), 79(5), e12851. https://doi.org/10.1111/aji.12851
  55. Gil, M. M., Quezada, M. S., Revello, R., Akolekar, R., & Nicolaides, K. H. (2015). Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound in Obstetrics & Gynecology: The Official Journal of The International Society of Ultrasound in Obstetrics and Gynecology, 45(3), 249–266. https://doi.org/10.1002/uog.14791
  56. Gregg, A. R., Skotko, B. G., Benkendorf, J. L., Monaghan, K. G., Bajaj, K., Best, R. G. … Watson, M. S. (2016). Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics. Genetics in Medicine: Official Journal of The American College of Medical Genetics, 18(10), 1056–1065. https://doi.org/10.1038/gim.2016.97
  57. Rolnik, D. L., da Silva Costa, F., Lee, T. J., Schmid, M., & McLennan, A. C. (2018). Association between fetal fraction on cell-free DNA testing and first-trimester markers for pre-eclampsia. Ultrasound in Obstetrics & Gynecology: The Official Journal of The International Society of Ultrasound in Obstetrics and Gynecology, 52(6), 722–727. https://doi.org/10.1002/uog.18993
  58. Salomon, L. J., Alfirevic, Z., Audibert, F., Kagan, K. O., Paladini, D., Yeo, G. … ISUOG Clinical Standards Committee (2014). ISUOG consensus statement on the impact of non-invasive prenatal testing (NIPT) on prenatal ultrasound practice. Ultrasound in Obstetrics & Gynecology: the Official Journal of The International Society of Ultrasound in Obstetrics and Gynecology, 44(1), 122–123. https://doi.org/10.1002/uog.13393